Inovio secures FDA nod for phase 2 segment of Covid-19 DNA vaccine candidate trial

Inovio has secured approval from the US Food & Drug Administration (FDA) to begin phase 2 segment of its planned phase 2/3 clinical trial for its Covid-19 DNA vaccine candidate.